Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Regulatory Authority Council (RAC) Letter - Q-Pan


Public Health Service

Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

Our STN: BL 125419/0

ID Biomedical Corporation of Quebec
(dba GlaxoSmithKline Biologicals)
Attention: Michael Schwartz, Ph.D.
2301 Renaissance Boulevard,
P.O. Box 61540
King or Prussia, PA 19406-2772

Dear Dr. Schwartz:

We have received your May 24, 2013, resubmission to your biologics license application for Influenza A (H5N1) Virus Monovalent Vaccine for active immunization for the prevention of disease in persons 18years of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine, on May 24, 2013

We consider this a complete, Class 2 response to our action letter. Therefore, the user fee goal date is November 23, 2013.

If you have any questions, please contact the Regulatory Project Managers, LCDR Jeremy Wally, Ph.D. or Kirk Prutzman, Ph.D., at (301) 796-2640.

Sincerely yours,

Wellington Sun, M.D.
Division of Vaccines and
Related Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 04/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English